Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > From $0.52 to $28.00 in 12 months or $3.5 to $23 in 3 months

<< Previous

Bullboard Posts

Next >>

Comment by inthnoon Jan 12, 2024 1:42pm

136 Views

Post# 35824018

RE:RE:RE:RE:RE:RE:RE:RE:RE:From $0.52 to $28.00 in 12 months or $3.5 to $23 in 3 months

Ok, Azzak, for you a most positive post.
Looks like we will only be down about 10% for the week so looking up as far as I can see.
Closed at 1.81 on Monday.

Now for another reality, let's hope they start the folfirinox, panc trial this quarter and also the panc phase 3 mid year. That is what this company needs. NO more small trials and then not continuing on.
So yes we are looking for either a partner or BO or share dilution.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec